A number of other research firms have also weighed in on HCM. Deutsche Bank assumed coverage on shares of HUTCHISON CHINA/S in a research note on Monday, March 4th. They issued a buy rating and a $26.82 price objective for the company. Zacks Investment Research lowered shares of HUTCHISON CHINA/S from a hold rating to a sell rating in a research note on Thursday, April 11th. Finally, HSBC assumed coverage on shares of HUTCHISON CHINA/S in a research note on Wednesday, March 27th. They issued a buy rating for the company. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. HUTCHISON CHINA/S has a consensus rating of Buy and a consensus target price of $26.82.
NASDAQ:HCM opened at $29.02 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.33 and a quick ratio of 4.19. The company has a market cap of $3.87 billion, a PE ratio of -50.91 and a beta of 1.10. The business has a 50 day moving average of $27.08. HUTCHISON CHINA/S has a 12 month low of $20.83 and a 12 month high of $39.68.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: What are no-load funds?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.